Mupiderm (Mupirocin)

Mupirocin inhibits bacterial isoleucyl‑tRNA synthetase, an enzyme required for protein synthesis. By blocking this enzyme, the drug prevents the incorporation of isoleucine into bacterial proteins, halting bacterial growth and leading to cell death. This action is selective for bacteria and does not affect human cells.

The appropriate dose and duration of Mupiderm are determined by the prescribing healthcare professional based on the specific infection, patient age, and severity. Patients should follow the prescriber's instructions and not alter the regimen without medical advice.

Safety data for mupirocin use in pregnancy and lactation are limited. The product’s pregnancy category is listed as unknown. Healthcare providers should weigh potential benefits against possible risks and discuss any concerns with the patient before prescribing.

To request Mupiderm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mupiderm (mupirocin) offers a narrow‑spectrum activity primarily against Staphylococcus aureus and Streptococcus pyogenes, making it effective for common skin infections while minimizing disruption of normal flora. Compared with broader agents such as bacitracin or neomycin, mupirocin has a lower risk of cross‑resistance and is often preferred for impetigo and folliculitis.

Mupiderm should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and extreme heat. Ensure the container is tightly closed when not in use to maintain stability.

Mupiderm is applied directly to the affected skin area, typically in a thin layer, after gentle cleansing and drying. The medication should be used as directed by the prescriber, usually two to three times daily, and the treated area should be covered with a sterile dressing only if advised.

Serious adverse reactions, though rare, include severe allergic responses such as angioedema, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and systemic hypersensitivity. Patients should seek immediate medical attention if they experience widespread rash, blistering, swelling, or signs of anaphylaxis.

Mupiderm should not be used by individuals with a known hypersensitivity to mupirocin or any component of the formulation. It is also contraindicated on mucous membranes, the eyes, or on extensive body surface areas without medical supervision.